title: D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects.
abstract: The purpose of this study was to compare striatal D2 dopamine receptor occupancy of various typical neuroleptics and clozapine in relation to the occurrence of extrapyramidal side effects (EPS). Forty-four inpatients with schizophrenia, including 12 patients with schizodominant schizoaffective disorder, were evaluated using 123I-iodobenzamide (IBZM) and single photon emission computed tomography. Striatal D2 dopamine receptor occupancy was estimated by use of a striatal/frontal cortex ratio (ST/FC) of IBZM binding. Fourteen patients were neuroleptic-free and served as controls. Six patients were treated with clozapine and 24 patients were treated with various typical neuroleptics. ST/FC ratios in patients taking typical neuroleptics were significantly lower than those who were neuroleptic free or treated with clozapine. Patients with EPS had lower ST/FC ratios than those without EPS. A significant linear relationship between ST/FC ratios and severity of EPS estimated by the Simpson-Angus-Scale was established (r=-0.51, p=0.041).
authors.affiliation: Klinik und Poliklinik für Psychiatrie der MLU Halle/S., Germany.
authors.forename: K
authors.initials: K
authors.lastname: Broich
authors.forename: F
authors.initials: F
authors.lastname: Grünwald
authors.forename: S
authors.initials: S
authors.lastname: Kasper
authors.forename: E
authors.initials: E
authors.lastname: Klemm
authors.forename: H J
authors.initials: HJ
authors.lastname: Biersack
authors.forename: H J
authors.initials: HJ
authors.lastname: Möller
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000378:metabolism*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging*; D001549:Benzamides; D003024:Clozapine / Q000009:adverse effects / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005625:Frontal Lobe / Q000000981:diagnostic imaging / Q000378:metabolism*; D006801:Humans; D008297:Male; D017072:Neostriatum / Q000000981:diagnostic imaging / Q000378:metabolism*; D011759:Pyrrolidines; D019275:Radiopharmaceuticals; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism*; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D014150:Antipsychotic Agents; D001549:Benzamides; D011759:Pyrrolidines; D019275:Radiopharmaceuticals; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D003024:Clozapine